Dermatomyositis (Connective Tissue Disease) Clinical Trials

A listing of Dermatomyositis (Connective Tissue Disease) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 183 clinical trials
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different COVID-19 vaccine booster doses in participants with autoimmune disease requiring immunosuppressive medications. All study participants will have negative serologic or sub-optimal responses (defined as a Roche Elecsys Anti-SARS-CoV-2 S (RBD) result 50 U/mL) to initial …

rituximab
hydroxychloroquine
lupus
disease or disorder
prednisone
  • 0 views
  • 24 Sep, 2021
  • 5 locations
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy

lupus
anifrolumab
  • 0 views
  • 12 Sep, 2021
  • 92 locations
A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

The purpose of the study is to assess the Safety, Tolerability, PK/PD and preliminary Efficacy of ICP-022 in Subjects with Systemic Lupus Erythematosus (SLE)

lupus
antinuclear antibody
  • 0 views
  • 31 May, 2021
  • 13 locations
Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter Randomised Placebo-controlled Trial

The management of active systemic lupus erythematosus (SLE) is challenging due to the heterogeneous nature of the disease and lack of specific treatment. Current treatment regimens mainly rely on corticosteroids and immunosuppressive agents which are associated with substantial adverse effects including various infections. Therefore, there is an unmet need for …

cyclophosphamide
immunosuppressive agents
hydroxychloroquine
lupus
mycophenolate
  • 5 views
  • 24 Jan, 2021
  • 1 location
The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus

This study evaluates the safety and efficacy of the traditional chinese medicine Zishenqing in the treatment of active systemic lupus erythematosus.

cyclosporine
hydroxychloroquine
lupus
mycophenolate
treatment regimen
  • 0 views
  • 24 Jan, 2021
  • 1 location
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases

The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children with rheumatic diseases (Systemic Lupus Erythematosus, Primary Sjgren Syndrome, Juvenile Idiopathic Arthritis).

rheumatic diseases
arthritis
lupus
sjogren's syndrome
interleukin-2
  • 0 views
  • 26 Jan, 2021
  • 1 location
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

This study to examines the impact of anifrolumab on disease activity, immune phenotypes, and development of neutralizing antibodies to quadrivalent influenza vaccine in patients with Systemic Lupus Erythematosus (SLE). 10 patients with moderately to severely active SLE will be treated with anifrolumab in addition to standard of care lupus treatments …

  • 0 views
  • 02 Feb, 2021
  • 5 locations
Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation

Diagnosis and follow up of a lupus cohort in a multidisciplinary consultation in Brest ( France)

  • 0 views
  • 28 Jan, 2021
  • 1 location
Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)

This is a Phase 1b, double blind, randomized, placebo-controlled study of the safety and tolerability, pharmacokinetics and pharmacodynamics of AC0058TA in patients with systemic lupus erythematosus (SLE).

  • 0 views
  • 23 Jan, 2021
  • 1 location
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases

Accelerated atherosclerosis is an established complication of systemic autoimmune diseases, particularly SLE. Young female patients with SLE are more likely to develop myocardial infarction than matched healthy controls, and CVD is nowadays one of the most common causes of death (27%) in lupus patients. While traditional CV risk factors cannot …

  • 0 views
  • 19 Mar, 2021
  • 4 locations